Cannabis Pharmaceuticals Forecast to Hit $111B by 2032 — A 24x Jump

The cannabis pharmaceuticals market is on track for one of the steepest growth curves in healthcare. A research report published in Dublin on May 18, 2026 estimates the global cannabis pharmaceuticals market at $4.7 billion in 2025 and projects it to reach $111.1 billion by 2032 — a compound annual growth rate of 57.1% over seven years. That is roughly a 24-fold expansion in a category that, only a decade ago, consisted of a handful of cannabis-derived medicines navigating a hostile regulatory environment.

The report, added to ResearchAndMarkets.com's offerings and circulated via GlobeNewswire under the title "Cannabis Pharmaceuticals Business Research Report 2026," names AbbVie, Aphria, Aurora Cannabis, Bausch Health and Canopy Growth among the companies anchoring the segment. For investors who have spent two years watching consumer cannabis multiples compress, the cannabis pharmaceuticals forecast points to where the next leg of growth in the broader cannabinoid economy may actually come from: clinical-grade products developed under traditional pharma rules, sold through traditional pharma channels.

What's Driving a 57% CAGR

A growth rate this aggressive almost never reflects organic consumer adoption. It reflects a category transitioning from niche to mainstream pharmaceutical practice, and several specific tailwinds in 2026 explain why analysts feel comfortable underwriting numbers that would look implausible in most other healthcare segments.

The most important is the federal Schedule III shift. Rescheduling cannabis to Schedule III removes some of the banking and capital-markets barriers that previously discouraged public offerings from cannabis pharmaceutical developers. As cannabis news outlets reported through May 2026, pharmaceutical companies developing cannabis-based therapeutics have been reviving listing plans on the back of the reclassification, and bankers are anticipating a meaningful uptick in cannabis-pharma deal flow with several developers testing investor appetite. That capital access matters enormously for a category whose unit economics depend on Phase 2 and Phase 3 clinical programs that cost hundreds of millions of dollars apiece.

The second driver is scientific validation. Cannabis-derived pharmaceuticals are emerging as a transformative segment within global healthcare, driven by increasing evidence for cannabinoid mechanisms across a widening list of indications. Epidiolex, GW Pharma's cannabidiol-based seizure medication, has spent half a decade demonstrating that a cannabis-derived drug can clear FDA review, build payer coverage and produce sustainable revenue inside a traditional pharma model. Sativex (nabiximols) has done similar work for multiple sclerosis spasticity in many markets outside the United States. The 2026 forecast assumes that the pipeline behind those products — for conditions ranging from epilepsy and MS to chronic pain, sleep disorders and certain cancers — finally starts delivering approvals at scale through the late 2020s.

A third tailwind is global. Several jurisdictions outside the U.S. have already legalized medical cannabis under pharmaceutical-style frameworks, fueling research and development efforts and leading to the approval of cannabis-derived drugs for conditions such as epilepsy, multiple sclerosis and chronic pain. Germany's medical cannabis imports have surged in 2026, the UK and Australia have built up specialist prescribing systems, and Latin American countries are increasingly issuing GMP-grade cannabinoid product approvals. A global market growing in parallel means cannabis pharmaceutical companies are not betting solely on the U.S. payer system.

How a $4.7B Segment Becomes $111B

To put the projection in scale, the cannabis pharmaceuticals market at $111.1 billion in 2032 would be roughly comparable to the current global market for diabetes drugs — a category built on decades of clinical evidence, payer infrastructure and patient adherence systems. Reaching that level in seven years requires several things to go right in sequence.

It requires the regulatory environment to keep moving in one direction. Schedule III is the foundational change, but follow-on actions — FDA guidance on cannabinoid drug development, DEA registration policies for cannabis pharma manufacturers, and payer coverage decisions on emerging therapeutics — all need to materialize on a reasonable timeline. The Schedule III aftershocks reshaping the industry outlook through 2026 are a necessary but not sufficient condition.

It requires the clinical pipeline to convert. Several developers are advancing programs in indications where current treatments leave significant unmet need: refractory pediatric epilepsy beyond Dravet and Lennox-Gastaut syndromes, treatment-resistant pain, palliative care, certain psychiatric conditions and rare neurological disorders. A 57% CAGR over seven years assumes a steady cadence of approvals — not a single blockbuster, but a portfolio of indications across multiple companies.

It requires capital to flow. The financing pattern bankers are anticipating — public listings, secondary offerings and pharma-style royalty deals — has to actually materialize. Cannabis pharmaceutical R&D is expensive, and the segment is still drawing capital away from a consumer cannabis market struggling with price compression and tax pressures. The May 2026 forecast effectively assumes that capital allocation will continue to tilt toward the pharma side of the cannabinoid economy.

The Companies Best Positioned

The report names AbbVie, Aphria, Aurora Cannabis, Bausch Health and Canopy Growth as featured operators in the segment. That is a notable mix: AbbVie and Bausch are traditional global pharmaceutical companies whose involvement signals that the category is no longer the exclusive domain of pure-play cannabis firms. Aphria (now part of Tilray's broader portfolio), Aurora Cannabis and Canopy Growth are the legacy Canadian cannabis pioneers that have been pivoting toward higher-margin pharma and medical export businesses as the recreational margin compresses.

Tilray, which absorbed Aphria, reported its third consecutive profitable quarter in fiscal Q3 2026 and has been steering capital toward international medical cannabis and a pharmaceutical partnership with Carlsberg. Canopy Growth has continued to refine its medical-cannabis pipeline and its Storz & Bickel medical vaporizer business. Aurora has rebuilt around its German and Australian medical channels and a sharply focused B2B pharma supply model. The forecast effectively treats these companies' bets on the medical side as the correct read of where cannabinoid economics are heading.

Outside the named operators, several pure-play cannabinoid pharma developers — Jazz Pharmaceuticals (which acquired GW Pharmaceuticals), Corbus Pharmaceuticals and a handful of clinical-stage CB receptor modulator companies — are also positioned to capture pieces of the projected growth. Whether the market fragments across many mid-sized winners or concentrates in a few platform companies is one of the open questions the May 2026 report leaves unanswered.

What Investors and Operators Should Take Away

A 57% CAGR projection should always be read with caution. Market-research forecasts that long are inherently uncertain, especially for a category whose regulatory base case keeps moving. But the directional signal is consistent with what is actually happening in 2026: the Schedule III shift, the cannabis-pharma deal pipeline, the cadence of clinical readouts and the global expansion of medical cannabis frameworks all point to a category that is graduating into pharmaceutical norms.

For operators, the takeaway is that the highest-value cannabinoid businesses of the next seven years may not be the dispensary brands consumers know. They may be GMP-grade manufacturers, clinical-stage drug developers and the contract research organizations supporting cannabis-pharma trials. For investors, it suggests that exposure to the cannabinoid economy is now best taken in two distinct buckets: consumer cannabis with all of its price and tax pressures, and cannabis pharmaceuticals on a fundamentally different trajectory.

Key Takeaways

• A May 18, 2026 report projects the global cannabis pharmaceuticals market will grow from $4.7B in 2025 to $111.1B by 2032 — a 57.1% CAGR.
• Schedule III reclassification, cannabis-pharma listings and improving capital access are the dominant near-term tailwinds.
• AbbVie, Aphria, Aurora Cannabis, Bausch Health and Canopy Growth are named among the segment's featured operators.
• The forecast effectively prices in steady FDA approvals across multiple cannabinoid indications through the late 2020s.
• The most valuable cannabinoid businesses by 2032 may be pharmaceutical developers, not consumer dispensary brands.

Explore cannabis news, find dispensaries, and join the community at Budpedia.